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The thermal inactivation conditions (75C35 min, 80C10 min, 85C5 min and 90C5 25 
min) for Protamex
TM
 following bovine whey protein concentrate (WPC) hydrolysis was 26 
studied with the view to limiting WPC hydrolysate (WPH) aggregation while maintaining 27 
bioactivity. A decrease in the amount of large WPH aggregates formed was observed at 28 
inactivation temperatures  85C. However, the WPC appeared to be more hydrolysed on 29 
heating at 75C35 min, as ProtamexTM was active for longer under these heating conditions. 30 
Significantly (p < 0.05) higher WPH antioxidant (oxygen radical absorbance capacity - 31 
ORAC) activity was obtained on inactivation at temperatures  80C. In contrast, the 32 
dipeptidyl peptidase IV (DPP-IV) inhibitory properties of all WPH samples were similar (p > 33 
0.05). A reduction in thermal treatment from 90C5 min to 85C5 min was sufficient to 34 
decrease the amount of large aggregates formed in the hydrolysate without altering its 35 
bioactive properties. 36 
Key words: Antidiabetic nutriceuticals, antioxidants, dairy products, diabetes, enzymes, food 37 
processing aspects, milk proteins, processing effects, protein hydrolysates, thermal effects, 38 





1 Introduction 42 
Enzymatic hydrolysis of dietary proteins is commonly used in the food industry to decrease 43 
allergenicity, increase bioactivity and digestibility, and to enhance technofunctional 44 
properties (Foegeding et al., 2002; Embiriekah et al., 2017). The enzyme employed during 45 
hydrolysis is usually inactivated to maintain hydrolysate stability during subsequent 46 
processing/storage (Whitehurst & Law, 2002). Hydrolysis reactions are generally terminated 47 
by thermal treatment and/or pH alteration, modifications which can irreversibly inactivate 48 
enzyme activity (Eijsink et al., 2005). Thermal treatments are preferred to avoid the addition 49 
of other chemicals to the final hydrolysate. However, heat treatment may lead to some 50 
structural rearrangements within proteins and peptides (Foegeding et al., 2002). Therefore, 51 
the conditions (pH, substrate concentration or the temperaturetime combination) employed 52 
during inactivation need to be carefully chosen to minimise protein and peptide aggregation, 53 
precipitation or gelation. 54 
At laboratory scale, enzymes are commonly inactivated in a batch manner by immersion of 55 
the samples in water baths (10-20 min) at high temperature (80-90C) (Nongonierma et al., 56 
2013; Whitehurst & Law, 2002). Selection of enzyme inactivation conditions 57 
(temperaturetime) appear to be solely based on their ability to suppress enzyme activity. 58 
However, the application of different temperaturetime combinations during heat treatment 59 
may lead to physicochemical differences between hydrolysates. Whey proteins are widely 60 
reported as a source of bioactive peptides (for reviews, see: Hernández-Ledesma et al., 2014; 61 
Morris & FitzGerald, 2009). However, whey proteins and whey protein-derived peptides are 62 
highly sensitive to heat treatment and may aggregate when exposed to elevated (> 65C) 63 
temperatures (Foegeding et al., 2002; Wijayanti et al., 2014). In order to limit heat-induced 64 
denaturation of whey proteins and whey protein-derived peptides, the temperature applied 65 
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during enzyme inactivation may be decreased while the duration of inactivation is increased 66 
(Conesa & FitzGerald, 2013). Nevertheless, the heat treatment conditions per se may have an 67 
impact on hydrolysate bioactivity (O'Loughlin et al., 2014; Adjonu et al., 2013). 68 
To our knowledge, the effect of enzyme inactivation conditions on hydrolysate 69 
physicochemical and bioactive properties does not seem to have been generally studied. The 70 
aim of this study was to assess the impact of four different temperaturetime combinations 71 
during enzyme inactivation of a whey protein hydrolysate (WPH) on its physicochemical 72 
(degree of hydrolysis (DH), molecular mass distribution, peptide profile and particle size 73 
distribution) and bioactive (dipeptidyl peptidase IV (DPP-IV) inhibition and oxygen radical 74 
absorbance capacity (ORAC)) properties. The inhibition of DPP-IV was used as an in vitro 75 
indicator of an antidiabetic effect, as its inhibition may be targeted for the improvement of 76 
serum glucose regulation in type 2 diabetes (Juillerat-Jeanneret, 2014). As a high oxidative 77 
status may occur in type 2 diabetics (Rani & Mythili, 2014), the ORAC value of the WPH 78 
samples was also determined. 79 
2 Materials and methods 80 
2.1 Reagents 81 
Whey protein concentrate (WPC, 81% (w/w) protein) was obtained from Carbery Group 82 
(Ballineen, Ireland). Protamex
TM
 was obtained from Novozymes (Bagsvaerd, Denmark). 83 
Mass spectrometry (MS) grade water and acetonitrile (MeCN), trifluoroacetic acid (TFA), 84 
trichloroacetic acid (TCA), azocasein, sodium phosphate monobasic, sodium phosphate 85 
dibasic, Gly-Pro-pNA, diprotin A (Ile-Pro-Ile), porcine DPP-IV (≥ 10 units mg-1 protein), 86 
tris(hydroxymethyl)aminomethane (TRIS), Trolox and 2,2’-azobis(2-87 
methylpropionamidine)dihydrochloride (AAPH) were purchased from Sigma Aldrich 88 
DOI: 10.1111/ijfs.13576 
5 
(Dublin, Ireland). Sodium hydroxide (NaOH) was obtained from VWR (Dublin, Ireland). 89 
2,4,6-Trinitrobenzenesulfonic acid (TNBS) was obtained from Pierce Biotechnology 90 
(Medical Supply Company, Dublin, Ireland). All other chemicals were obtained from Sigma 91 
Aldrich and were of analytical grade unless otherwise stated. 92 
2.2 Determination of heat inactivation conditions of Protamex 93 
Protamex
TM
 was dispersed in distilled water at a concentration of 0.2% (w/w), which 94 
corresponded to the same dosage as that used during enzymatic hydrolysis of whey proteins 95 
(section 2.3). Immediately after enzyme suspension, this solution was immersed in a water 96 
bath set at 75, 80, 85 or 90C. Samples were then withdrawn at 5, 10, 15, 25, 40 and 50 min. 97 
The enzyme activity in the samples was subsequently determined using the azocasein assay 98 
(Kilcawley et al., 2002) with modifications. Briefly, 500 µL of azocasein 0.5% (w/w) was 99 
mixed with 500 µL sample and incubated at 50°C for 30 min. The reaction was terminated by 100 
addition of 2 M TCA (100 µL). The absorbance was measured at 440 nm in a 101 
spectrophotometer (Cary 100 Bio UV-visible, Varian, Palo Alto, CA, USA). Subsequently, 102 
the temperaturetime combinations required to inactivate ProtamexTM in aqueous solution 103 
were applied to the whey protein hydrolysate (see section 2.3.) to verify that there was no 104 
residual proteolytic activity remaining in the hydrolysate. The residual enzyme activity was 105 
expressed relative to the activity present in a sample which was not heat inactivated (100% 106 
enzyme activity). Each experiment was carried out in triplicate (n=3). 107 
2.3 Enzymatic hydrolysis of whey proteins 108 
WPC (10% (w/w) on a protein basis) was rehydrated in distilled water at 50C for 1 h under 109 
gentle agitation. The solution was adjusted to pH 7.0 using NaOH (2 M). Protamex
TM
, was 110 
added at an enzyme to substrate ratio (E:S) of 2% (w/w) and hydrolysis was carried out at 111 
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50C for 3 h without pH regulation. The enzyme was heat inactivated using different 112 
temperaturetime combinations, i.e., 75C35 min (WPH-75C35 min), 80C10 min 113 
(WPH-80C10 min), 85C5 min (WPH-85C5 min) or 90C5 min (WPH-90C5 min). 114 
Negative controls consisted of the WPC solution (10% (w/w) on a protein basis) which was 115 
not heated following 3 h incubation at 50C (WPC-control 50C) and WPC-control 50C 116 
which was heat inactivated under the same conditions as the WPH samples, i.e., at 75C35 117 
min (WPC-75C35 min), 80C10 min (WPC-80C10 min), 85C5 min (WPC-85C5 118 
min) or 90C5 min (WPC-90C5 min). All hydrolysis reactions and heat inactivation 119 
conditions were performed in triplicate (n=3). Samples were then freeze-dried (FreeZone 120 
18L, Labconco, Kansas City, MO, USA) and stored at -20C. 121 
2.4 Determination of the DH using the TNBS method 122 
DH was determined in triplicate (n=3) using the TNBS method adapted to microplate format 123 
(Le Maux et al., 2016). Leucine was used as a standard (at concentrations ranging from 0 to 4 124 
mM) to allow determination of the primary amino group content of the samples (AN, in mg 125 
N mg
-1
 sample). DH was calculated using the following formula: 126 
% 𝐷𝐻 =  
𝐴𝑁𝑊𝑃𝐻 − 𝐴𝑁 𝑊𝑃𝐶− 𝑐𝑜𝑛𝑡𝑟𝑜𝑙 50℃
𝑁𝑝𝑏
× 100 
The amino group content of the peptide bonds (Npb) for whey proteins was 123.3 mg g
-1
. 127 
2.5 Determination of the molecular mass distribution by sodium dodecyl sulphate 128 
polyacrylamide gel electrophoresis (SDS-PAGE) and gel permeation ultra-129 
performance liquid chromatography (GP-UPLC) 130 
The molecular mass distribution of the samples was analysed using SDS-PAGE. Mini-131 
PROTEAN TGX precast gels (4-20% resolving gel, Bio-Rad Laboratories Inc., Hercules, 132 
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CA, USA) were run on a Mini Protean II system (Bio-Rad) according to the manufacturer’s 133 
instructions. Samples were separated under non-reducing and reducing (β-mercaptoethanol) 134 
conditions. A broad range molecular weight calibration kit (6.5 to 200 kDa, Bio-Rad) was 135 
used as molecular weight marker. Gels were stained with Coomassie brilliant blue and 136 
subsequently scanned using an Odyssey imaging system (LI-COR, Lincoln, NE, USA). The 137 
intensities of the bands were analysed by densitometry using the GelAnalyser 2010a software 138 
(http://www.gelanalyzer.com/) (Lazer & Lazer, 2010). 139 
GP-UPLC was also used for determination of molecular mass distribution as previously 140 
described (Le Maux et al., 2017). Samples were analysed in triplicate (n=3) on an Acquity 141 
UPLC system equipped with an Acquity BEH125 SEC column (4.6 × 150 mm, 1.7 µm) and 142 
an Acquity BEH125 SEC 1.7 μm vanguard pre-column, all from Waters (Milford, MA, 143 
USA). A mobile phase composed of MeCN/H2O/TFA (30.0:69.9:0.1, v/v/v) was used to elute 144 
samples (injected at a protein equivalent content of 20 µg) at a flow rate of 0.3 mL min
-1
 for 8 145 
min at 30C. The molecular mass standards ranged from 67,500 to 181 Da. Results were 146 
expressed as the proportion of the peak area obtained at 214 nm within different molecular 147 
mass ranges: < 1, 1-5, 5-10 and > 10 kDa. 148 
2.6 Peptide profile analysis by reverse phase (RP)-UPLC 149 
Samples were analysed by RP-UPLC using a Waters Acquity UPLC system as described by 150 
Le Maux et al. (2015) with some modifications. Briefly, RP-UPLC was performed using an 151 
Acquity BEH C18 column (2.1 x 50 mm, 1.7 µm) equipped with an Acquity BEH C18 1.7 152 
μm vanguard pre-column (Waters). Solvent A was MeCN/H2O/TFA (1.0:98.9:0.1, v/v/v) and 153 
solvent B was MeCN/H2O/TFA (90.0:9.9:0.1, v/v/v). For each sample, 56.7 µg protein 154 
equivalent was injected onto the column. A linear gradient from 100 to 40% solvent A was 155 
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applied for 60 min at a flow rate of 0.2 mL min
-1
. The column temperature was maintained at 156 
40ºC. 157 
2.7 Particle size analysis by laser light scattering 158 
The particle size distribution of the hydrolysates (WPH-75C35 min, WPH-80C10 min, 159 
WPH-85C5 min and WHP-90C5 min) and controls (WPC-control 50C, WPC-75C35 160 
min, WPC-80C10 min, WPC-85C5 min and WPC-90C5 min) was determined with a 161 
Malvern Mastersizer 2000 equipped with an Hydro 2000S sample dispersion system (1000 162 
rpm stirring speed), interfaced with Mastersizer 2000 software (version 5.61, Malvern 163 
Instruments, Malvern, UK). Samples were analysed at a concentration of 8.1 mg mL
-1
 on a 164 
protein equivalent basis. Each sample was analysed in triplicate (n=3) and three 165 
measurements were taken with a 10 s delay. The relative refractive and absorbance indexes 166 
were set at 1.56 and 0.001, respectively. The continuous phase (distilled water) refractive 167 
index was 1.33. The volume weighted mean (D [4,3]) was reported as the mean particle size. 168 
2.8 Determination of the antioxidant capacity using the ORAC assay 169 
The antioxidant capacity of each sample was determined using the ORAC assay as described 170 
previously (Nongonierma et al., 2015). Briefly, samples were tested at a final concentration 171 
of 8.1 µg L
-1
 on a protein equivalent basis. Samples were resuspended in 75 mM phosphate 172 
buffer pH 7.0. Trolox was used as a positive control at final concentrations ranging from 0 to 173 
8 µM. Samples (50 µL) and fluorescein (50 µL, final concentration 0.1 µM) were mixed in a 174 
96 well microplate (Thermo Fisher Scientific, Waltham, MA, USA), which was incubated at 175 
37°C for 15 min in a microplate reader (Biotek Synergy HT, Winoosky, VT, USA). The 176 
reaction was initiated by the addition of 25 µL of AAPH radical (final concentration 14.63 177 
mM). The fluorescence was monitored over 60 min at excitation and emission wavelengths of 178 
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485 and 520 nm, respectively. The ORAC values were expressed as μmol of Trolox 179 
equivalents (TE) per g of protein equivalent. Each sample was analysed in triplicate (n=3). 180 
2.9 DPP-IV inhibition assay 181 
The DPP-IV inhibitory activity of the hydrolysates was determined as described by 182 
Nongonierma & FitzGerald (2013a). Briefly, samples were tested at final concentrations 183 
ranging from 1.010-2 to 2.5 mg mL-1 on a protein equivalent basis. The positive control, Ile-184 
Pro-Ile was assessed at final concentrations ranging from 12.510-2 to 12.5 µg mL-1. Samples 185 
(25 μL) were mixed with Gly-Pro-pNA (final concentration 0.200 mM) in a 96 well 186 
microplate (Sarstedt, Dublin, Ireland). DPP-IV (final concentration 0.0025 U mL
-1
) was 187 
added to the wells to initiate the reaction and the microplate was incubated at 37C for 60 188 
min in a microplate reader (Biotek Synergy HT). Absorbance of the pNA released was 189 
monitored at 405 nm. The DPP-IV half maximal inhibitory concentration (IC50) was 190 
determined by plotting the percentage inhibition as a function of WPH concentration 191 
expressed in mg protein equivalents mL
-1
. Each sample was analysed in triplicate (n=3). 192 
2.10 Statistical analysis 193 
Results are presented as the mean ± SD (n=3). Results were compared by ANOVA with a 194 
Tukey’s test at a significance level (p < 0.05). To check the absence of enzyme activity in the 195 
heat-treated WPH samples, the residual enzyme activity was analysed with a one-sample 196 
Student test (t-test, p < 0.05). All statistical analyses were performed with the R software 197 
3.1.0 package and the Rcmdr library version 2.1-7 (R Foundation for Statistical Computing, 198 
Vienna, Austria). 199 
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3 Results and discussion 200 
3.1 Residual enzyme activity of ProtamexTM after heat inactivation 201 
Preliminary experiments were performed to assess the role of heating time and temperature 202 
on inactivation of the proteolytic activity in Protamex
TM
. The different temperaturetime 203 
combinations led to a decrease in enzyme activity (Supplementary Fig. S1A-S1D). As 204 
expected, some residual activity was still found in the samples on heating at lower 205 
temperatures and shorter times. For example, at 75C5 min the residual activity of 206 
Protamex
TM
 was of 15.89 ± 12.95% (Supplementary Fig. S1A). However, on incubation, the 207 
proteolytic activity was not significantly different from zero (p > 0.05) at times  25, 10, 5 208 
and 5 min on heating at 75, 80, 85 and 90°C, respectively. 209 
On the basis of the above results, the heat inactivation conditions applied to the hydrolysates 210 
were 75°C30 min, 75°C35 min, 80°C10 min, 85°C5 min and 90°C5 min. The residual 211 
proteolytic activity in the WPH samples after heat inactivation in the above conditions is 212 
illustrated in Fig. 1. The residual proteolytic activity in the hydrolysates was not significantly 213 
different from zero (p > 0.05) for the WPH-75C35 min, WPH-80C10 min, WPH-85C5 214 
min and WPH-90C5 min samples. Therefore, these conditions were selected for further 215 
studies on heat inactivation of the WPH samples. 216 
3.2 DH of WPH samples 217 
The DH of the WPH samples ranged from 7.1 ± 0.2% to 7.5 ± 0.8% for WPH-85C5 min 218 
and WPH-80C10 min, respectively (Table 1). All the DH values of the WPH samples were 219 
of the same order (p > 0.05), regardless of the heat inactivation conditions employed. An 220 
increase in DH at lower inactivation temperatures was not evidenced, possibly due to the fact 221 
that the TNBS method may not be able to detect small variations in DH. 222 
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3.3 Molecular mass distribution of WPH samples by SDS-PAGE and GP-UPLC 223 
Bands representing the major whey proteins, i.e., β-lactoglobulin (β-lg), α-lactalbumin (α-la) 224 
and bovine serum albumin (BSA), were observed in the WPC-control 50C, WPC-75C35 225 
min, WPC-80C10 min, WPC-85C5 min and WPC-90C5 min on the SDS-PAGE gels 226 
(Supplementary Fig. S2). It was also evident that the WPC-75C35 min, WPC-80C10 227 
min, WPC-85C5 min and WPC-90C5 min samples contained large aggregates that did 228 
not enter the gel under non-reducing conditions (Supplementary Fig. S2A). However, under 229 
reducing conditions, WPC-75C35 min, WPC-80C10 min, WPC-85C5 min and WPC-230 
90C5 min displayed a similar SDS-PAGE profile to the WPC-control 50C 231 
(Supplementary Fig. S2B). This highlighted the impact of heat processing on whey proteins 232 
aggregation and the role of disulphide linkage in same. 233 
Large aggregates (unable to enter the gels) were also visible in the WPH profiles obtained 234 
with the non-reducing conditions (Supplementary Fig. S2A). These aggregates were 235 
dissociated under reducing conditions and able to enter the gel (Supplementary Fig. S2B). 236 
Densitometric analysis of the gels obtained under reducing conditions showed a lower 237 
proportion of β-lg (34.9%) and BSA (1.4%) in the WPH-75C35 min compared to the other 238 
three WPH samples. In addition, there was an increased proportion of low molecular mass 239 
compounds (< 13 kDa) from 12.7 ± 1.5% to 39.5 ± 3.9% for WPH-90C5 min and WPH-240 
75C35 min, respectively (Fig. 2A). 241 
The molecular mass distribution profile of the WPH samples, as determined by GP-UPLC 242 
(Fig. 2B), showed that protein (> 10 kDa) hydrolysis occurred within all the WPH samples. 243 
Interestingly, there was a lower proportion of proteins (> 10 kDa) in the WPH samples 244 
inactivated at 75C35 min (24.4 ± 4.3%) compared to inactivation at 85C5 min (31.5 ± 245 
1.6%, Fig. 2B). The differences between WPH samples observed using GP-UPLC were not 246 
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as obvious compared to the SDS-PAGE results, which may be due to the fact that larger 247 
aggregates may have been retained during the filtration (0.22 µm) step prior to GP-UPLC 248 
analysis. 249 
Overall, the SDS-PAGE profiles indicate that in WPH-75C35 min, a higher extent of β-lg 250 
and BSA degradation was seen compared to that in the other samples. The greater breakdown 251 
of β-lg together with the appearance of low molecular mass compounds (< 13 kDa) seen in 252 
the WPH samples heat inactivated at 75C35 min (Fig. 2A-2B and Supplementary Fig. S2) 253 
may be explained by the fact that the proteolytic activity within Protamex
TM
 was active for 254 
longer immediately prior to denaturation (Whitehurst & Law, 2002; Johnson et al., 1967). 255 
Increasing enzyme inactivation temperature during WPH processing produced larger 256 
aggregates (Fig. 2A-2B and Supplementary Fig. S2). The larger aggregates seen in 257 
hydrolysates inactivated at temperatures  85C may be linked to the higher proportion of 258 
intact proteins (i.e., β-lg and BSA) in these hydrolysates compared to WPH-75C35 min 259 
(Fig. 2A). In addition, this may also be due to the fact that whey proteins and peptides within 260 
WPH can aggregate and gel with increasing temperature (Foegeding et al., 2002; Donovan & 261 
Mulvihill, 1987; Puyol et al., 2001; Wijayanti et al., 2014). This may also be related to the 262 
fact that accessibility of thiol groups increases at higher temperatures, which accelerates the 263 
aggregation rate via thiol/disulphide exchange reactions (de Wit, 2009; Wijayanti et al., 264 
2014). 265 
3.4 Peptide profile of WPH samples by RP-UPLC 266 
The peptide profiles of WPC-control 50C and WPH samples were analysed by RP-UPLC 267 
(Fig. 3). This analysis was carried out to visualise protein breakdown following enzymatic 268 
hydrolysis and also to understand the potential role of heat inactivation on the peptides 269 
released in WPH samples. The results show a decreased peak intensity, corresponding to the 270 
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major whey proteins (β-lg, α-la and BSA) eluting between 30 and 50 min, which was 271 
observed in all WPH samples compared to the WPC-control 50C. This decrease in peak 272 
intensity of intact whey proteins is more pronounced for WPH samples heat inactivated at 273 
WPH-75C35 min and WPH-80C10 min (Fig. 3). Some differences in peptide peak 274 
intensities were seen in the four WPH samples. In particular in WPH-75C35 min, 5 peptide 275 
peaks eluting before 35 min were more intense than in the other three samples (Fig. 3). 276 
Peptides eluted at different retention times, which suggested that the WPH samples contained 277 
peptides having a wide range of hydrophobicity. In line with the molecular mass distribution 278 
profiles determined by SDS-PAGE (Fig. 2A and Supplementary Fig. S2), the RP profiles also 279 
show a higher extent of β-lg breakdown in the WPH-75C35 min sample compared to the 280 
other three hydrolysates. 281 
3.5 Particle size distribution 282 
The WPC-control 50C was mainly composed of small particles, having a D [4, 3] of 6.1 ± 283 
0.4 µm (Table 1). The particles within the 3 h WPH sample measured immediately prior to 284 
heat inactivation had a D [4, 3] value of 2.1 ± 0.1 µm. The D [4, 3] values of WPH-75C35 285 
min, WPH-80C10 min, WPH-85C5 min and WPH-90C5 min were not significantly 286 
different from each other (Table 1, p > 0.05). However, differences could be observed 287 
between the particle size profiles obtained for WPH-90C5 min and the other WPH samples 288 
(Supplementary Fig. S3). A relatively lower volume was observed for the smaller particle 289 
population (~20 µm) in WPH-90C5 min sample compared to the other WPH samples. This 290 
explains the higher mean D [4, 3] value for the WPH-90C5 min samples (181.9 ± 29.1 µm) 291 
compared to the three other WPH samples (e.g., 146.2 ± 36.3 µm for WPH-80C10 min). 292 
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In the absence of heat treatment, smaller sized peptide-peptide and peptide-protein aggregates 293 
ranging between 1.4 and 7.5 kDa (Creusot et al., 2006) or having a D [4, 3] values between 294 
49.9 to 67.0 µm (Spellman et al., 2005) have been reported within WPH samples generated 295 
with certain enzyme preparations. In the study herein, however, no aggregation occurred 296 
prior to the heat inactivation step, showing that the formation of aggregates within WPH 297 
samples was heat-induced. Aggregation between proteins/peptides may be due to both 298 
disulphide aggregation and non-covalent interactions, which may explain the bimodal 299 
distribution of the particles within the WPH samples (de Wit, 2009; Wijayanti et al., 2014; 300 
Simmons et al., 2007). β-Lg aggregates formed as a consequence of non-covalent interactions 301 
should be larger at heating temperatures between 75 and 85C than those formed between 85 302 
and 105C (de Wit, 2009). The different temperature-dependent behaviour of -lg may 303 
explain the fact that small size (< 100 µm) peptide-peptide and peptide-protein aggregates 304 
can be formed within the WPH samples via non-covalent interactions when heat treated 305 
between 75 and 85C (Creusot et al., 2006; Spellman et al., 2005). 306 
3.6 Antioxidant and DPP-IV inhibitory activity of WPH samples 307 
The DPP-IV IC50 values of all the WPH samples were lower than that of the WPC-control 308 
50C (Table 1). Samples with a low IC50 value are more potent inhibitors of DPP-IV. The 309 
higher potency of the WPH samples is linked to the release of DPP-IV inhibitory peptides 310 
during hydrolysis. The mean DPP-IV IC50 values of the WPH samples ranged from 1.29 ± 311 
0.21 to 1.41 ± 0.21 mg protein equivalent mL
-1
 for WPH-80C10 min and WPH-90C5 312 
min, respectively. However, there was no significant difference between the DPP-IV IC50 313 
values for the WPH samples (p > 0.05). 314 
The ORAC activity of the WPH samples was significantly higher than the WPC-control 50C 315 
(p < 0.05, Table 1). The ORAC activity of the WPH samples ranged from 179.5 ± 25.3 to 316 
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227.6 ± 37.1 µmol TE g
-1
 protein equivalent for WPH-85C5 min and WPH-80C10 min, 317 
respectively. The ORAC value for WPH-75C35 min and WPH-80C10 min were 318 
significantly higher than that of WPH-85C5 min and WPH-90C5 min (p < 0.05). The 319 
higher ORAC values obtained with the WPH samples heated at 75 and 80C may be 320 
explained by the fact that these WPH samples may have been relatively more hydrolysed 321 
(Fig. 2A, Fig. 3 and Supplementary Fig. S2) than WPH samples heated at 85 and 90C. As a 322 
result of a higher extent of protein breakdown in WPH-75C35 min and WPH-80C10 min 323 
(Fig. 2A, Fig. 3 and Supplementary Fig. S2), it is possible that additional antioxidant peptides 324 
may have been released during heat inactivation at 75 and 80C compared to hydrolysates 325 
inactivated at 85 and 90C. The peptide peak differences seen, for example, in WPH-326 
75C35 min (Fig. 3) may be linked to the higher ORAC activity of this sample. The 327 
differences in aggregation behaviour of peptides within the different hydrolysates inactivated 328 
at different temperaturetime combination (Supplementary Fig. S3) may also impact on the 329 
results observed. In general highly aggregated peptides are not soluble in water and therefore, 330 
in the ORAC assay they may not be able to scavenge the AAPH radical. This is in agreement 331 
with the observation that samples presenting a higher level of aggregation (i.e., WPH-85C5 332 
min and WPH-90C5 min, Supplementary Fig. S3) displayed a lower antioxidant activity. 333 
Specific peptide sequences within food protein hydrolysates have been identified for their 334 
antioxidant and DPP-IV inhibitory activities (Lacroix & Li-Chan, 2016; Power et al., 2013). 335 
These peptides can differ in length and general physicochemical properties. The ORAC 336 
activity and DPP-IV IC50 values observed herein were of the same order as those reported for 337 
other WPH samples in the literature. For instance, the DPP-IV inhibitory potency of whey 338 
proteins hydrolysed for 4 h with a food-grade gastro-intestinal preparation (Nongonierma & 339 





 and 1.33 ± 0.17 mg mL
-1
, respectively. An ORAC value of 336.8 ± 24.3 µmol TE g
-1
 341 
protein equivalent was described for WPC hydrolysed with pepsin for 2 h (Conway et al., 342 
2013). A tryptic digest of -lg obtained after 24 h hydrolysis had an ORAC value 467.7 ± 343 
25.0 µmol TE. g
-1
 dry weight (Power et al., 2014). 344 
4 Conclusions 345 
This study demonstrates the importance of carefully selecting WPH enzyme thermal 346 
inactivation conditions. Under the conditions used herein, a reduction of inactivation 347 
temperature from 90C to 85C was sufficient to decrease the proportion of large aggregates 348 
in the WPH samples. However, decreasing the temperature to 75C, which was associated 349 
with a longer enzyme inactivation time, did not allow further reduction in the amount of large 350 
aggregates formed. The peptide composition of the WPH samples may be linked to their 351 
bioactive properties. Differences were seen in the peptide profiles of WPH samples as a 352 
function of the heat treatment applied. These did not alter DPP-IV inhibitory properties of the 353 
WPH samples, while they had an effect on their ORAC activities. This study has 354 
demonstrated that the enzyme activity per se should not be the only parameter considered 355 
when selecting heat inactivation temperaturetime conditions for WPH samples. It is not 356 
recommended to decrease the heat inactivation temperature of Protamex
TM
 WPH samples 357 
below 85C as the longer time required for enzyme inactivation may modify sample 358 
physicochemical properties (aggregation, peptide profile), which in turn may impact on its 359 
bioactivity (e.g., ORAC and DPP-IV inhibitory activities). Future work may include study of 360 
the impact of temperaturetime combinations employed during heat inactivation of WPH at 361 
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Table 1. Percentage degree of hydrolysis (DH), volume weighted mean D [4,3], oxygen 467 
radical absorbance capacity (ORAC) value and dipeptidyl peptidase IV (DPP-IV) half 468 
maximal inhibitory concentration (IC50) of whey protein control (WPC-control 50C) and 469 
whey protein hydrolysate (WPH) samples heat inactivated under different temperaturetime 470 
combinations (75C35 min (WPH-75C35 min), 80C10 min (WPH-80C10 min), 471 
85C5 min (WPH-85C5 min) or 90C5 min (WPH-90C5 min)). The DPP-IV IC50 472 
value of Ile-Pro-Ile, the positive control, was 3.69 ± 0.68 µM. All ORAC and DPP-IV IC50 473 
values are expressed in protein equivalents. Values represent the mean ± SD of three 474 
replicates (n = 3). For each assay, values with different superscript letters are significantly 475 














WPC-control 50˚C na 6.1 ± 0.4
 a
 62.4 ± 22.0
 a
 > 2.5  
WPH-75˚C35 min 7.3 ± 0.4 
a
 154.2 ± 47.0
 b
 220.3 ± 25.9
 b
 1.35 ± 0.17 
a
 
WPH-80˚C10 min 7.5 ± 0.8 
a
 146.2 ± 36.3
 b
 227.6 ± 37.1
 b
 1.41 ± 0.21 
a
 
WPH-85˚C5 min 7.1 ± 0.2 
a
 152.8 ± 30.1
 b
 179.5 ± 25.3
 c
 1.32 ± 0.23 
a
 
WPH-90˚C5 min 7.3 ± 0.2 
a










Figure captions 479 
 480 
Figure 1. Residual enzyme activity of ProtamexTM measured with the azocasein assay (50C 481 
for 30 min incubation) in the whey protein hydrolysate (WPH) samples heat inactivated at 482 
75C30 min (WPH-75C30 min), 75C35 min (WPH-75C35 min), 80C10 min 483 
(WPH-80C10 min), 85C5 min (WPH-85C5 min) and 90C5 min (WPH-90C5 484 
min). Values represent the mean ± SD of three replicates (n = 3). ns: residual enzyme activity 485 
not significantly different from 0 (p > 0.05), *: residual enzyme activity significantly 486 
different from 0 (p < 0.05). 487 
 488 
Figure 2.  (A) Densitometric analysis of the molecular mass distribution of the 489 
proteins/peptides in the test sample determined by sodium dodecyl sulphate polyacrylamide 490 
gel electrophoresis (SDS-PAGE) under reducing conditions and (B) protein/peptide 491 
molecular mass distribution determined by gel permeation ultra-performance liquid 492 
chromatography (GP-UPLC) of whey protein control (WPC-control 50C) and whey protein 493 
hydrolysate (WPH) samples heat inactivated under different temperaturetime combinations 494 
(75C35 min (WPH-75C35 min), 80C10 min (WPH-80C10 min), 85C5 min 495 
(WPH-85C5 min) or 90C5 min (WPH-90C5 min)). The molecular weight markers 496 
used for SDS-PAGE were 200.0, 116.3, 97.4, 66.2, 45.0, 31.0, 21.5, 14.4 and 6.5 kDa. 497 
Compounds less than 13 kDa were labelled as “low molecular mass compounds”. 498 
Compounds between 32 and 56 kDa were labelled as “large molecular mass compounds”. 499 
Values represent the mean ± SD of three replicates (n = 3). For GP-UPLC, bovine serum 500 
albumin (BSA), -lactoglobulin (-lg), -lactalbumin (-la), aprotinin, bacitracin, Leu-trp-501 
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Met-Arg, Asp-Glu and Tyr were used as standards. Values represent the mean ± SD of three 502 
replicates (n = 3). 503 
 504 
Figure 3. Representative reverse-phase ultra-performance liquid chromatography (RP-505 
UPLC) profiles obtained at 214 nm for (1) whey protein control (WPC-control 50C) and 506 
whey protein hydrolysate (WPH) heat inactivated at (2) 75C35 min (WPH-75C35 min), 507 
(3) 80C10 min (WPH-80C10 min), (4) 85C5 min (WPH-85C5 min) and (5) 90C5 508 
min (WPH-90C5 min). The arrows indicate peptide peaks were major differences are seen 509 
between WPH-75C35 min and the three other WPH samples. 510 
 511 
Supplementary Figure S1. Residual enzyme activity of Protamex
TM
 measured with the 512 
azocasein assay (50C for 30 min incubation) after heat inactivation in distilled water at (A) 513 
75, (B) 80, (C) 85 and (D) 90C for 5, 10, 15, 25, 40 and 50 min. Values represent the mean ± 514 
SD of three replicates (n = 3). ns: residual enzyme activity not significantly different from 0 515 
(p > 0.05), *: residual enzyme activity significantly different from 0 (p < 0.05). 516 
 517 
Supplementary Figure S2. Representative sodium dodecyl sulphate polyacrylamide gel 518 
electrophoresis (SDS-PAGE) profiles under (A) non-reducing and (B) reducing conditions of 519 
whey protein control (WPC-control 50C) and whey protein hydrolysate (WPH) heat 520 
inactivated under different temperaturetime combinations (75C35 min (WPH-75C35 521 
min), 80C10 min (WPH-80C10 min), 85C5 min (WPH-85C5 min) or 90C5 min 522 
(WPH-90C5 min)) and their respective control (WPC-75C35 min, WPC-80C10 min, 523 
WPC-85C5 min and WPC-90C5 min). BSA: bovine serum albumin; β-lg: β-524 
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lactoglobulin; α-la: α-lactalbumin; MW, molecular weight markers (200.0, 116.3, 97.4, 66.2, 525 
45.0, 31.0, 21.5, 14.4 and 6.5 kDa). 526 
 527 
Supplementary Figure S3. Particle size distribution profiles of (1) whey protein control 528 
(WPC-control 50C) and whey protein hydrolysate (WPH) heat inactivated at (2) 75C35 529 
min, (3) 80C10 min, (4) 85C5 min and (5) 90C5 min. Values represent the mean ± SD 530 
of three replicates (n = 3). 531 
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